The stated purpose is to meet NYSE American's per-share price requirements; authorized shares will fall to 11,666,666 before adjusted trading begins Dec. 2.
Obefazimod is in Phase 3 trials for moderately to severely active ulcerative colitis; Abivax says results will support its U.S. FDA NDA filing by year-end.
If the average daily discount exceeds 7.50% during the July 8-Sept. 30, 2027 period, the fund intends to offer to repurchase at least 5% of outstanding shares at 98% of NAV.
Cheung is scheduled to speak from 9:35 to 10:05 a.m. Mountain Standard Time; Mark Grant will join investor meetings, and audio will be available in replay.
The lab aims to develop AI-driven production methods for oat-derived ingredients and test purity, safety and elemental and isotopic profiles to support standards.
The presentation is scheduled for 8:20 a.m. Eastern time at the 9th Annual Evercore Healthcare Conference, with a live webcast on its investor relations site.